Labcorp Drug Development, formerly Covance, is a global contract research organization (CRO) and a segment of Labcorp. It provides a wide array of services to the pharmaceutical and biotechnology industries, supporting clients from early-stage research and preclinical studies through all phases of clinical trials (Phase I-IV) and into market access. Key services include central laboratory services, clinical trial management, bioanalytical services, early development research, and regulatory consulting. Labcorp Drug Development aims to accelerate the delivery of innovative medicines to patients by leveraging its scientific expertise, global reach, and advanced technologies.
Serves as a key operational and strategic center for Labcorp's global drug development services, including clinical operations, project management, and scientific leadership.
The Princeton campus is part of a larger office park environment, typically featuring modern office buildings and potentially specialized laboratory or data management facilities suited for CRO operations.
Characterized by a focus on scientific rigor, collaboration, innovation, and client service in the fast-paced pharmaceutical development sector. Emphasis on quality, ethics, and patient impact.
Represents a significant center for global pharmaceutical research and development services, building on Covance's long history in the CRO industry.
Labcorp Drug Development supports global clinical trials and drug development programs with a significant presence across North America, Europe, Asia-Pacific, Latin America, and Africa. Functions supported globally include Phase I-IV clinical trial management, central laboratory services, bioanalytical testing, preclinical research, regulatory consulting, market access solutions, and companion diagnostics development. This extensive network allows them to conduct complex, multi-regional studies for pharmaceutical and biotechnology clients worldwide.
210 Carnegie Center Drive
Princeton
New Jersey
USA
Address: 8201 Scicor Drive, Indianapolis, IN 46214, USA (Example of a major site)
Serves as a critical hub for Labcorp's central laboratory services in North America and globally, providing key data for clinical research.
Address: Route de la Corniche 4, 1066 Epalinges, Switzerland (Example, specific address may vary)
Facilitates engagement with European pharmaceutical clients, regulatory bodies, and investigator sites; supports pan-European clinical studies.
Address: 11 Biopolis Way, #06-01/08 Helios, Singapore 138667 (Example of a major site)
Provides critical infrastructure and expertise for conducting clinical research in the growing Asia-Pacific pharmaceutical market, catering to both global and regional clients.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Labcorp Drug Development' leadership includes:
Labcorp Drug Development has been backed by several prominent investors over the years, including:
Labcorp periodically announces executive changes at the corporate level, which may impact its Drug Development segment. Specific news for the Drug Development segment leadership is often part of broader Labcorp announcements. In the last 12-18 months, Labcorp has had several key corporate appointments.
Discover the tools Labcorp Drug Development uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Labcorp Drug Development, as part of Labcorp, generally uses standardized email formats common for large corporations. The most prevalent format is firstname.lastname@labcorp.com. Variations might exist but are less common.
firstname.lastname@labcorp.com
Format
john.doe@labcorp.com
Example
90%
Success rate
Labcorp Press Release / Business Wire • February 15, 2024
Labcorp announced its fourth-quarter and full-year 2023 financial results, with the Drug Development segment (formerly Covance) reporting revenues of $3.16 billion for Q4, an increase of 6.0% from $2.98 billion in Q4 2022. Full-year 2023 revenues for Drug Development were $12.18 billion, up 4.7%. The growth was attributed to continued demand in clinical development and central laboratory services....more
Labcorp Press Release / Business Wire • October 26, 2023
Labcorp announced the appointment of Amy Sumrall as executive vice president and chief marketing officer. In this role, Sumrall will lead Labcorp’s global marketing strategy and execution, impacting brand perception and go-to-market strategies for all segments, including Drug Development....more
Fierce Biotech • July 27, 2023
Labcorp's drug development arm saw demand stabilize in the second quarter of 2023 after a more challenging start to the year. Executives noted a pickup in RFPs and awards, particularly in oncology and early-phase research, indicating a healthier outlook for CRO services....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Labcorp Drug Development, are just a search away.